Business
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to a 16-point HQ-CT reduction, with an average reduction of approximately 8 points among subjects that followed trial protocol) observed during the 28-day dosing period. DEXA scans analysis from the PWS Phase 2 trial data measuring body composition indicated a trend toward decreased body fat (approximately
About this update from Aardvark Therapeutics, Inc.
[{"type":"image","alt":"Aardvark Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Aardvark Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/fe55bd926bdb60296161677c87a21101"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_2n1g9xWdfu1GQlbvtkO7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/fe55bd926bdb60296161677c87a21101","width":300,"height":63}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to a 16-point HQ-CT reduction, with an average reduction of approximately 8 points among subjects that followed trial protocol) observed during the 28-day dosing period. ","length":362,"tagName":"p"}]},{"val":[{"type":"text","content":"DEXA scans analysis from the PWS Phase 2 trial data measuring body composition indicated a trend toward decreased body fat (approximately 1.5%) and increased lean muscle (over 2%) following 28 days of ARD-101 dosing.","length":216,"tagName":"p"}]},{"val":[{"type":"text","content":"Ongoing ARD-101 Phase 3 HERO trial to treat hyperphagia associated with PWS is expected to generate topline data in early 2026.","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Aardvark bolstered its cash runway through the successful completion of its Initial Public Offering (IPO) in February 2025.","length":123,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":828,"olType":false},{"type":"text","content":"SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the full year ended December 31, 2024, and provided business highlights.","length":391,"tagName":"p"},{"type":"text","content":"“Appetite represents a reward-based neurological drive and hunger represents a penalty or pain avoidance neurological drive. Many approved obesity medications, including GLP-1RA agents, primarily r...